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To the editor: The emergence of a novel pathogen 
raises a wide range of urgent questions that need to be 
addressed to guide clinical and public health responses 
[1]. One of the cornerstones and a prerequisite for a 
proper public health and clinical response is the avail-
ability of a reliable diagnostic and reference laboratory 
service with adequate capacity. This is recognised in 
the International Health Regulations (IHR 2005) and 
explicitly recognised by the World Health Organization 
(WHO) and the European Centre for Disease Prevention 
and Control (ECDC) in their risk assessments and guide-
lines upon the emergence of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) [2–5]. Colson 
et al. question the proportionality of the laboratory 
readiness and response for this novel coronavirus in 
expert laboratories of Emerging Viral Diseases-Expert 
Laboratory Network (EVD-LabNet) and European 
Reference Laboratory Network for Human Influenza 
(ERLI-Net) in 30 European Union and European 
Economic Area (EU/EEA) countries, as outlined in our 
publication [6]. The initial response to the emergence 
of SARS-CoV-2 is a strategy of containment consisting 
of active case finding in combination with case isola-
tion and quarantine of contacts [3], a strategy for which 
adequate worldwide laboratory services are indispen-
sable as seeding of the virus through travellers from 
China could be expected. Indeed, during the response 
period for our survey, the first cases of coronavirus dis-
ease 2019 (COVID-19) were already notified in France 
on 24 January and as at 26 February 2020, 381 cases 
have been notified in Europe [6,7].
While the current response strategy is still focused 
on containment, it is becoming increasingly clear that 
the epidemic may turn global, in which case mitiga-
tion will be the next option to control the impact of 
the pandemic. Substantial autochthonous circulation 
in Italy, Iran and South Korea has been reported by 
now, while there is increasing evidence that subclinical 
infections occur and people may be infectious before 
symptoms appear [8–10]. These developments indicate 
that the window of opportunity to contain and eradi-
cate is rapidly narrowing. Colson et al. remark that “the 
emergence of SARS-CoV-2 in December 2019 repro-
duced this pattern of disproportionate fear of impor-
tation and spread in mainland France while the cases 
reported worldwide remain almost only localised in 
China as only 34 people died of this disease (COVID-19) 
outside China” thus may rapidly become invalid with 
the increasing instances of ongoing transmission in 
locations outside China. Already in the past 24 h (25 
to 26 February 2020), nine new deaths outside China 
were reported [11]. Therefore, it is needless to state 
that for each phase in the control and mitigation of a 
novel emerging pathogen, adequate laboratory prepar-
edness and response are crucial. The readiness survey 
that we performed served the important purpose of 
mapping the initial response capacities in Europe and 
identifying barriers to diagnostic implementation.
Therefore, we maintain that the urgent implementa-
tion and monitoring of diagnostic capacities and capa-
bilities for SARS-CoV-2 in Europe is proportional to the 
containment and expected mitigation phase of the 
global public health response and is critical for care 
of local patients. The implementation of SARS-CoV-2 
diagnostics does not replace nor exclude diagnos-
tic capacity for other respiratory viruses. Moreover, it 
explicitly does not disregard the importance of other 
seasonal respiratory pathogens for public and patient 
health. This is clearly illustrated by the authors them-
selves, who indicate that they have tested thousands 
of samples of patients suspected of respiratory viral 
disease not only for common respiratory pathogens but 
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also for SARS-CoV-2. The fact that Colson et al. found 
a wide range of seasonal respiratory viruses indeed 
underlines the impact of such pathogens. Furthermore, 
it clearly shows that diagnosis of respiratory viruses 
cannot be done syndrome-based and supports the 
need for the availability of diagnostics for a panel of 
pathogens including SARS-CoV-2.
The proportionality of the measures taken to control 
SARS-CoV-2 can only be rightly evaluated when the 
critical questions related to SARS-CoV-2, including the 
exact mortality rate highlighted by the authors, have 
been answered. These answers are already largely 
known for the common seasonal respiratory viruses 
but until then cautiousness, is needed. Regardless of 
the outcomes of the rapidly evolving epidemiological 
situation of SARS-CoV-2 and even in the event that 
SARS-CoV-2 becomes the fifth commonly circulating 
human coronavirus, the need for diagnostic capacity 
and capability will remain.
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